| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 广州必贝特医药股份有限公司由“国家重大人才工程”特聘专家钱长庚教授及其团队于2012年1月在广州科学城高新技术产业开发区创立，是一家以临床价值为导向、专注于创新药自主研发的生物医药企业。公司聚焦于肿瘤、自身免疫性疾病、代谢性疾病等重大疾病领域，依托自主研发构建的核心技术平台，持续开发临床急需的全球首创药物（First-in-Class）和针对未满足临床需求的创新药物。公司秉承“以临床价值为导向，专注原创新药研发，矢志创新，追求更好”的经营宗旨，坚持自主创新，致力于研发出具有全球自主知识产权、安全、有效的创新药物。公司管理团队、核心技术人员和专家团队包括多名海归博士、国家重大人才工程特聘专家、企业家和运营管理人才，具有丰富的国内外药物研发经验和企业运营管理经验，先后入选广州开发区科技领军人才、广东“珠江人才计划”创新创业团队和广州市创业领军团队。公司先后被授予广东省博士后创新实践基地、被认定为广东省国家一类新药发现和产业化工程技术研究中心，并获评广州“未来独角兽”创新企业和广州“高精尖”企业等。 | ||||||||||||||||||||||||
| Main Business | 创新药物的研发、生产和销售。 | ||||||||||||||||||||||||
| Legal Representative | 钱长庚 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 张天翼 | ||||||||||||||||||||||||
| Solicitors | 湖南启元律师事务所 | ||||||||||||||||||||||||
| Auditors | 中审众环会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 020-32038086 | ||||||||||||||||||||||||
| Fax No | 020-32038086 | ||||||||||||||||||||||||
| Website | www.bebettermed.cn | ||||||||||||||||||||||||
| ir@bebettermed.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 28/10/2025 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ -0.160 | ||||||||||||||||||||||||
| DPS(RMB)* | -- | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 0.810 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.480B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |